Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Hagop M. Kantarjian; Timothy P. Hughes; Richard A. Larson; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Carla Boquimpani; Ricardo Pasquini; Richard E. Clark

doi:10.1038/s41375-020-01111-2

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Identifier:nobleid.org/w1/20260526/3FADDFC2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3FADDFC2.svg?ark=w1%2F20260526%2F3FADDFC2)](https://nobleid.org/work/w1/20260526/3FADDFC2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Identifier:nobleid.org/w1/20260526/3FADDFC2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3FADDFC2.svg?ark=w1%2F20260526%2F3FADDFC2)](https://nobleid.org/work/w1/20260526/3FADDFC2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work